Phar 12.06 Authorized distributors of record. A manufacturer shall maintain and update at least once per month a list of the manufacturer's authorized distributors of record.
SECTION 2. Phar 13.02 (3m) is created to read:
Phar 13.02 (3m) “Department" means the department of regulation and licensing.
SECTION 3. Phar 13.02 (6) is renumbered 13.02 (12) and is amended to read:
Phar 13.02 (12) “Distributor" “Wholesale distributor" means any a person engaged in
the wholesale distribution of prescription drugs or devices, including, but not limited to, manufacturers; repackers repackagers; own-label distributors; private-label distributors; jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug warehouses, and wholesale drug warehouses; manufacturers' exclusive distributors; manufacturers' authorized distributors of record; prescription drug wholesalers and distributors; independent wholesale prescription drug traders; and pharmacies that conduct wholesale distributions not coincident to the compounding, packaging, labeling and dispensing of prescription drugs and devices 3rd party logistics providers; retail pharmacies that conduct wholesale distribution; and chain pharmacy warehouses that conduct wholesale distribution.
SECTION 4. Phar 13.02 (8) and (9) are amended to read:
Phar 13.02 (8) “Facility" means a location at which where a wholesale distribution operations are conducted distributor stores, handles, repackages, or offers for sale prescription drugs.
(9) “Manufacturer" means any a person who is engaged in manufacturing, preparing, propagating, compounding, processing, packaging, repackaging, or labeling of a prescription drug or device licensed or approved by the federal food and drug administration to engage in the manufacture of drugs or devices, consistent with the definition of “manufacturer" under the federal food and drug administration's regulations and interpreted guidance implementing the federal prescription drug marketing act.
SECTION 5. Phar 13.02 (11) (intro.) and (a) are amended to read:
Phar 13.02 (11) (intro.) “Wholesale distribution" means distribution of a prescription drugs or devices to persons drug to a person other than a consumer or patient. The term does not include, but does not include any of the following:
(a) Intracompany sales, of prescription drugs which include any transaction or transfer between any division, subsidiary, parent, affiliated or related company under the common ownership and or control of a corporate entity or any transaction between co-licensees or a co-licensed product.
SECTION 6. Phar 13.02 (11) (b) to (e) are repealed.
SECTION 7. Phar 13.02 (11) (b) to (d) are created to read:
Phar 13.02 (11) (b) The sale, purchase, distribution, trade, or transfer of a prescription drug or offer to sell, purchase, distribute, trade, or transfer a prescription drug for emergency medical reasons.
(c) The distribution of prescription drug samples, if the distribution is permitted under
21 CFR 353 (d).
(d) Drug returns, when conducted by a hospital, health care entity, or charitable institution as provided in
21 CFR 203.23.
SECTION 8. Phar 13.02 (11) (f) is renumbered 13.02 (11) (e).
SECTION 9. Phar 13.02 (11) (f) to (m) are created to read:
Phar 13.02 (11) (f) The sale, purchase, or trade of a drug, an offer to sell, purchase, or trade a drug, or the dispensing of a drug pursuant to a prescription.
(g) The sale, transfer, merger, or consolidation of all or part of the business of a pharmacy from or with another pharmacy, whether accomplished as a purchase and sale of stock or business assets.
(h) The sale, purchase, distribution, trade, or transfer of a prescription drug from one authorized distributor of record to one additional authorized distributor of record, if the manufacturer states in writing to the receiving authorized distributor of record that the manufacturer is unable to supply the drug and the supplying authorized distributor of record states in writing that the drug has previously been exclusively in the normal distribution channel.
(i) The delivery of, or offer to deliver, a prescription drug by a common carrier solely in the common carrier's usual course of business of transporting prescription drugs, if the common carrier does not store, warehouse, or take legal ownership of the drug.
(j) A transaction excluded from the definition of “wholesale distribution" under
21 CFR 203.3 (cc).
(k) The donation or distribution of a prescription drug under s.
255.056, Stats.
(L) The transfer from a retail pharmacy or pharmacy warehouse of an expired, damaged, returned, or recalled prescription drug to the original manufacturer or original wholesale distributor or to a 3rd-party returns processor or reverse distributor.
(m) The return of a prescription drug, if the return is authorized by the law of this state.
SECTION 10. Phar 13.03 and 13.04 are repealed.
SECTION 11. Phar 13.05 (2) is amended to read:
Phar 13.05 (2) Pass an inspection of the facility conducted by the board or its representative
in the 3-year period immediately preceding the date of the application by the board, a pharmacy examining board of another state, the National Association of Boards of Pharmacy, or another accrediting body recognized by the board, with the date of each inspection to determine if the location meets standards specified in ss.
Phar 13.08 to
13.11, 21 USC 351 and 352 and 21 CFR 211.142 (b).
SECTION 12. Phar 13.055 is created to read:
Phar 13.055 Surety bond, irrevocable letter of credit. The applicant shall supply a surety bond or irrevocable letter of credit in the amount of $5,000.00, which is issued by a company authorized to do business in Wisconsin. The form of the bond or letter of credit shall be approved by the department and conditioned so that the state shall be fully compensated or reimbursed for, and shall be used to, secure payment of fees or costs that relate to the issuance of a wholesale distributor's license that have not been paid within 30 days after the fees or costs have become final. The bond or letter shall be valid for the entire period of an unexpired license issued to the applicant. No claim may be made against a bond or other security under this section more than one year after the date on which the applicant's wholesale distributor's license expires.
SECTION 13. Phar 13.06 (3) is repealed.
SECTION 14. Phar 13.08 is amended to read:
Phar 13.08 Personnel. A distributor shall employ adequate personnel with the education and experience necessary to safely and lawfully engage in the wholesale distribution of drugs and devices.
SECTION 15. Phar 13.09 (intro.) and (3) are amended to read:
Phar 13.09 Facility requirements. (intro.) All facilities at which prescription drugs or devices are stored, warehoused, handled, held, offered, marketed, or displayed shall:
(3) Have a quarantine area for storage of prescription drugs or devices that are outdated, damaged, deteriorated, misbranded, or adulterated, or that are in immediate or sealed secondary containers that have been opened;
SECTION 16. Phar 13.10 (3) is amended to read:
Phar 13.10 (3) Entry into areas where prescription drugs or devices are held is limited to authorized personnel;
SECTION 17. Phar 13.11 (1) to (4) are amended to read:
Phar 13.11 Storage requirements. (1) All prescription drugs and devices stored in a facility shall be stored at appropriate temperatures and under appropriate conditions in accordance with requirements, if any, in the labeling of such products, or with requirements in the current edition of an official compendium.
(2) If no storage requirements are established for a prescription drug or device, the product may be held at a controlled room temperature, as defined in an official compendium, to help ensure that its identity, strength, quality, and purity are not adversely affected.
(3) Appropriate manual, electromechanical, or electronic temperature and humidity recording equipment, devices, and/or or logs shall be utilized to document proper storage of prescription drugs and devices.
(4) The recordkeeping requirements in s.
Phar 13.14 shall be followed for all stored drugs
and devices.
SECTION 18. Phar 13.12 (1) to (3) are amended to read:
Phar 13.12 Examination of materials requirements. (1) Upon receipt by a facility, each outside shipping container shall be visually examined for identity and to prevent the acceptance of contaminated prescription drugs or devices, or prescription drugs or devices that are otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents.
(2) Each outgoing shipment from a facility shall be carefully inspected for identity of the prescription drug or device and to ensure that there is no delivery of prescription drugs or devices that have been damaged in storage or held under improper conditions.
(3) The recordkeeping requirements in s.
Phar 13.14 shall be followed for all incoming and outgoing prescription drugs
and devices at a facility.
SECTION 19. Phar 13.13 (title) and (1) to (4) are amended to read:
Phar 13.13 (title) Returned, damaged and outdated prescription drug and device requirements. (1) Prescription drugs and devices in a facility that are outdated, damaged, deteriorated, misbranded, or adulterated shall be quarantined and physically separated from other prescription drugs and devices until they are destroyed or returned to their supplier.
(2) Any prescription drugs or devices in a facility whose immediate or sealed outer or sealed secondary containers have been opened or used shall be identified as such, and shall be quarantined and physically separated from other prescription drugs and devices until they are either destroyed or returned to the supplier.
(3) If the conditions under which a prescription drug or device has been returned to a facility cast doubt on the product's safety, identity, strength, quality, or purity, then the product shall be destroyed, or returned to the supplier, unless examination, testing, or other investigation proves that the product meets appropriate standards of safety, identity, strength, quality, and purity. In determining whether the conditions under which a product has been returned cast doubt on its safety, identity, strength, quality, or purity, the distributor shall consider, among other things, the conditions under which the product has been held, stored, or shipped before or during its return and the condition of the product and its container, carton, or labeling, as a result of storage or shipping.
(4) The recordkeeping requirements in s.
Phar 13.14 shall be followed for all outdated, damaged, deteriorated, misbranded, or adulterated prescription drugs
and devices.
SECTION 20. Phar 13.14 (1) (intro.) and (a) to (c), and (2) are amended to read:
Phar 13.14 Recordkeeping requirements. (1) (intro.) A distributor shall establish and maintain inventories and records of all transactions regarding the receipt and distribution or other disposition of prescription drugs and devices. These records shall include the following information:
(a) The source of the drugs or device, including the name and principal address of the seller or transferor, and the address of the location from which the drugs or devices were shipped;
(b) The identity and quantity of the drugs or devices received and distributed or disposed of; and
(c) The dates of receipt and distribution or other disposition of the drugs or devices.
(2) Inventories and records shall be made available for inspection and copying by the board, its authorized representatives, and authorized representatives of federal, state and local law enforcement agencies for a period of 2 3 years following distribution or other disposition of the drugs or devices.
SECTION 21. Phar 13.15 (intro.), (1), (2) (intro.) and (b), and (4) are amended to read:
Phar 13.15 Written policies and procedures. (intro.) A distributor shall establish, maintain, and adhere to written policies and procedures, which shall be followed for the receipt, security, storage, inventory, and distribution of prescription drugs and devices, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. A distributor shall include in their written policies and procedures the following:
(1) A procedure to ensure that the oldest approved stock of a prescription drug or device is distributed first. The procedure may permit deviation from this requirement if the deviation is temporary and appropriate.
(2) (intro.) A procedure to be followed for handling recalls and withdrawals of prescription drugs and devices. The procedure shall be adequate to deal with recalls and withdrawals due to:
(b) Any voluntary action by the manufacturer to remove defective or potentially defective drugs or devices from the market; or
(4) A procedure to ensure that any outdated prescription drugs or devices are segregated from other products and either returned to the manufacturer or destroyed. This procedure shall provide for written documentation of the disposition of outdated prescription drugs or devices. This documentation shall be maintained for 2 3 years after disposition of the outdated drugs or devices.
SECTION 22. Phar 13.16 is amended to read:
Phar 13.16 Responsible persons. A distributor shall establish and maintain lists of officers, directors, managers, and other persons the designated representative in charge of wholesale drug and device distribution, storage, and handling, including a description of their duties and a summary of their qualifications.
SECTION 23. Phar 13.17 (1) is amended to read:
Phar 13.17 Compliance with federal, state and local laws. (1) A distributor shall operate in compliance with applicable federal, state, and local laws and regulations. A distributor shall operate in compliance with any applicable federal electronic track and trace pedigree system implemented after July 1, 2011, unless an earlier implementation date is mandated by federal law which explicitly preempts state law. A distributor that deals in controlled substances shall register with the drug enforcement administration.
Finding of Emergency
The board has made a finding of emergency. The board finds that failure to have the proposed rules in effect on June 1, 2008, the effective date of the applicable provisions of
2007 Wisconsin Act 20, will create a danger to the public health, safety and welfare, by disrupting the wholesale distribution of prescription drugs in the state of Wisconsin.
Notice of Hearing
Pharmacy Examining Board
NOTICE IS HEREBY GIVEN that the Pharmacy Examining Board will hold a public hearing at the time and place indicated below to consider an order to repeal sections
Phar 13.02 (11) (b) to
(e),
13.03,
13.04 and
13.06 (3); to renumber section
Phar 13.02 (11) (f); to renumber and amend section
Phar 13.02 (6); to amend sections
Phar 13.02 (8),
(9),
(11) (intro.) and
(a),
13.05 (2),
13.08,
13.09 (intro.) and
(3),
13.10 (3),
13.11 (1) to
(4),
13.12 (1) to
(3),
13.13 (title) and
(1) to
(4),
13.14 (1) (intro.),
(a) to
(c), and
(2),
13.15 (4),
13.16 and
13.17 (1); and to create sections
Phar 13.02 (3m),
(11) (b) to
(d),
(f) to
(m) and
13.055, relating to the regulation of wholesale prescription drug distributors.
Hearing Information
Date: July 23, 2008
Time: 9:45 a.m.
Location: 1400 East Washington Avenue
(Enter at 55 North Dickinson Street)
Room 121A
Madison, Wisconsin
Appearances at Hearing and Submission of Written Comments
Interested persons are invited to present information at the hearing. Persons appearing may make an oral presentation but are urged to submit facts, opinions and argument in writing as well. Facts, opinions and argument may be submitted in writing without a personal appearance by mail addressed to the Department of Regulation and Licensing, Office of Legal Counsel, P.O. Box 8935, Madison, Wisconsin 53708 or by email at
pamela.haack@drl.state.wi.us. Written comments must be received by July 25, 2008, to be included in the record of rule-making proceedings.
Agency Contact Person
Pamela Haack, Paralegal, Department of Regulation and Licensing, Office of Legal Counsel, 1400 East Washington Avenue, Room 152, P.O. Box 8935, Madison, Wisconsin 53708; telephone 608-266-0495; email at pamela.haack@ drl.state.wi.us.
Analysis Prepared by the Department of Regulation and Licensing
Statutes interpreted
